前列腺癌原发灶再程放疗后的决策后悔
这项双中心横断面探索性研究调查了31例前列腺癌原发灶再程放疗患者(21例接受HDR-BT,10例接受SBRT),使用决策后悔量表(DRS)评估决策后悔。平均DRS评分为10(SD:14),45%无后悔、48%轻度后悔、7%强烈后悔;决策后悔与泌尿症状负担和毒性等患者报告结局及共享决策水平显著相关,与再程放疗方式、进一步局部复发和无进展生存无关。
要点
- 再程放疗后决策后悔总体轻微,平均DRS评分10分(SD:14)。
- 48%患者报告轻度后悔,7%报告强烈后悔,45%无后悔。
- 决策后悔与泌尿症状负担、毒性及共享决策水平显著相关。
核心结论
- 前列腺癌原发灶再程放疗后患者决策后悔总体轻微。
- 症状负担和共享决策等患者报告结局可能与决策后悔相关。
研究设计与样本
- 双中心横断面探索性研究,调查31例前列腺癌原发灶再程放疗患者。
- 再程放疗方式为高剂量率近距离放疗(HDR-BT)21例和立体定向体部放疗(SBRT)10例。
- 使用决策后悔量表(DRS,范围0-100,分值越高后悔越强)测量决策后悔。
主要发现
- 再程放疗时中位年龄75岁,从初始放疗到再程放疗的中位间隔为8年,从再程放疗到调查的中位间隔为4年。
- 平均DRS评分为10(SD:14);无后悔(0分)、轻度后悔(1-25分)和强烈后悔(>25分)分别占45%(14/31)、48%(15/31)和7%(2/31)。
- 决策后悔与泌尿症状负担和毒性等患者报告结局以及共享决策水平和患者满意度显著相关。
- HDR-BT与SBRT、进一步局部复发和无进展生存与决策后悔无关。
关键数值与推荐
- DRS评分范围0-100分,0分为无后悔,1-25分为轻度后悔,>25分为强烈后悔。
临床怎么用
- 对于前列腺癌原发灶再程放疗,应关注泌尿症状负担和毒性等患者报告结局,并加强共享决策以可能减少决策后悔。
- 再程放疗方式(HDR-BT vs. SBRT)的选择可能不影响决策后悔,但需进一步验证。
局限性
- 样本量小(31例),为横断面探索性研究,结果需验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A subset of prostate cancer patients develops local relapse at the primary site after radiotherapy. The optimal local salvage strategy is unknown. Therefore, we aimed to explore prevalence and determinants of decision regret among patients after reirradiation of the primary site. MATERIALS AND METHODS: We surveyed 31 patients in a cross-sectional bi-centre exploratory study. Reirradiation was high dose-rate brachytherapy (HDR-BT) in 21 and stereotactic body radiotherapy (SBRT) in 10 patients. Decision regret (DR) was measured using the Decision Regret Scale (DRS) (range: 0-100; higher values higher regret). Further patient-reported outcomes (PRO) included the EPIC-26, EORTC QLQ-C30, PRO-CTCAE, and PSCC questionnaires. Univariable associations of decision regret and potential determinants were assessed by one-way ANOVA or Pearson's correlation. RESULTS: Median age at reirradiation was 75 years. Median time intervals from initial radiotherapy to reirradiation was 8 years and 4 years from reirradiation to survey. The mean DRS score was 10 (SD: 14). No (0 points), mild (1-25 points), or strong regret (>25 points) was reported by 45 % (14/31), 48 % (15/31), and 7 % (2/31) of the patients, respectively. DR was significantly associated with PRO of urinary symptom burden and toxicity as well as levels of shared-decision making and patient satisfaction. HDR-BT vs. SBRT, further local relapse, and progression-free survival were not associated with DR. CONCLUSIONS: DR was mild among prostate cancer patients after reirradiation to the primary site. PRO on symptom burden and shared decision making may be associated with DR. These findings should be validated and may inform treatment decisions on local salvage therapy.
引用
- Fabian A, Öztürk BS, Haack L, et al. Decision regret after reirradiation of the primary site in patients with prostate cancer. Clin Transl Radiat Oncol. 2025. PMID: 40761289. doi:10.1016/j.ctro.2025.101019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。